New vaccines against RSV and bird flu enter human testing

NCT ID NCT07516418

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Apr 09, 2026 · Last updated May 25, 2026 · Updated 6 times

Summary

This early-stage study tests the safety and immune response of experimental vaccines for respiratory syncytial virus (RSV) and a type of bird flu (H5N1) in 570 healthy adults aged 18 to 49. Participants will receive one or two shots, and researchers will monitor side effects and measure antibody levels over several months. The goal is to find safe vaccine formulas for further development.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Site # 036006
RECRUITING

Taringa, Queensland, 4068, Australia
Site # 03610004
RECRUITING

South Brisbane, Queensland, 4104, Australia
Site # 0361001
RECRUITING

Herston, Queensland, 4006, Australia
Site # 0361002
RECRUITING

Griffith, Queensland, 4222, Australia
Site # 0361003
RECRUITING

Morayfield, Queensland, 4506, Australia
Site # 0361005
RECRUITING

Sippy Downs, Queensland, 4556, Australia

Conditions

Explore the condition pages connected to this study.

INFLUENZA A(H5N1) RESPIRATORY SYNCYTIAL VIRUS (RSV) RESPIRATORY SYNCYTIAL VIRUS (RSV)